Researchers at Nagoya University in Japan have found that KD025, a drug already approved to treat an immune disease, shows promise for treating cognitive symptoms of schizophrenia.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Existing drug shows promise for memory and decision-making issues affecting most schizophrenia patients
Dendritic Spines Drug restores neural connections
Unlike Current Antipsychotics No side effects at effective doses
Faster Path To Human Trials Existing safety trials
23 Million global patients
Over 80% with cognitive dysfunction